Further studies on the safety of polymerized antigens for immunotherapy.
Six patients receiving immunotherapy with standard aqueous extracts for the treatment of atopic disease were selected from the patient population of Northwestern University Allergy Clinics for continued immunotherapy with polymerized antigens. These six patients could not tolerate quantities of conventional aqueous extracts considered maintenance doses because of immediate-type local or systemic allergic reactions or both to immunotherapy. These six patients were treated with separate preparations of polymerized ragweed (PRW) and polymerized grass (PG), and each of the six patients was rapidly advanced to previously unobtainable maintenance doses of PRW and PG without local or systemic reactions. Treatment with other aeroallergen standard extracts was continued to maintenance dosage without further systemic reactions. In patients highly sensitive to ragweed and grass aqueous extracts, the substitution of these extracts with PRW and PG allows these patients to receive therapeutic immunotherapy injections with decreased risk of immediate-type local and systemic reactions.
D000328:Adult; D000941:Antigens / Q000592:standards*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011108:Polymers / Q000592:standards*
D000941:Antigens; D011108:Polymers